Loading...
Antibody-drug conjugates and their potential in the treatment of patients with biliary tract cancer
Alexander, Shaun Aleem, Umair Jacobs, Timothy Frizziero, Melissa Foy, Victoria McNamara, Mairead G
Alexander, Shaun
Aleem, Umair
Jacobs, Timothy
Frizziero, Melissa
Foy, Victoria
McNamara, Mairead G
Citations
Altmetric:
Abstract
Background: Biliary tract cancers (BTCs) are aggressive in nature, often presenting asymptomatically until they are diagnosed at an advanced stage. Surgical resection or liver transplantation are potential curative options. However, a large proportion of patients present with incurable locally advanced or metastatic disease and most of these patients are only eligible for palliative chemotherapy or best supportive care. More recently, targeted therapies have proven beneficial in a molecularly selected subgroup of patients with cholangiocarcinoma who have progressed on previous lines of systemic treatment. However, only a minority of patients with BTCs whose tumours harbour specific molecular alterations can access these therapies. Methods: In relation to ADCs, studies regarding use of antibody-drug conjugates in cancer, particularly in BTCs, were searched in Embase (1974 to 2024) and Ovid MEDLINE(R) (1946 to 2024) to obtain relevant articles. Examples of current clinical trials utilising ADC treatment in BTCs were extracted from the ClinicalTrials.gov trial registry. Conclusions: Overall, this review has highlighted that ADCs have shown encouraging outcomes in cancer therapy, and this should lead to further research including in BTCs, where treatment options are often limited. The promising results observed with ADCs in various cancers underscore their potential as a transformative approach in oncology, warranting continued exploration and development and the need for education on the management of their specific toxicities. By addressing current challenges and optimising ADC design and application, future studies could potentially improve treatment outcomes for patients with BTCs and beyond, potentially in both early and advanced stage settings.
Description
Date
2024
Publisher
Collections
Files
Keywords
Type
Article
Citation
Alexander S, Aleem U, Jacobs T, Frizziero M, Foy V, Hubner RA, et al. Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer. Cancers (Basel). 2024 Sep 30;16(19). PubMed PMID: 39409965. Pubmed Central PMCID: PMC11476249. Epub 2024/10/16. eng.